Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Ophthalmological side effects of interferon therapy of chronic hepatitis C.

Medhat E, Esmat G, Hamza E, Abdel Aziz A, Fouad Fathalah W, Darweesh SK, Zakaria Z, Mostafa S.

Hepatobiliary Surg Nutr. 2016 Jun;5(3):209-16. doi: 10.21037/hbsn.2015.12.14.

2.

Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection.

Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A.

Mater Sociomed. 2014 Jun;26(3):172-6. doi: 10.5455/msm.2014.26.172-176.

3.

Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.

Evon DM, Esserman DE, Howell MA, Ruffin RA.

Pharmacopsychiatry. 2014 Sep;47(6):195-201. doi: 10.1055/s-0034-1385929.

4.
5.

Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines.

Ali L, Idrees M, Ali M, Hussain A, Ur Rehman I, Ali A, Iqbal SA, Kamel EH.

BMC Res Notes. 2014 Apr 17;7:247. doi: 10.1186/1756-0500-7-247.

6.

Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

Sever M, Newberry KJ, Verstovsek S.

Leuk Lymphoma. 2014 Dec;55(12):2685-90. doi: 10.3109/10428194.2014.893310. Review.

7.
8.
9.
10.
11.

PEGylated Adenoviruses: From Mice to Monkeys.

Wonganan P, Croyle MA.

Viruses. 2010 Feb;2(2):468-502. doi: 10.3390/v2020468.

12.

Review.

Taliani G, Biliotti E.

Gastroenterol Hepatol (N Y). 2007 Aug;3(8):646-7. No abstract available.

13.

Peginterferon and ribavirin treatment for hepatitis C virus infection.

Tsubota A, Fujise K, Namiki Y, Tada N.

World J Gastroenterol. 2011 Jan 28;17(4):419-32. doi: 10.3748/wjg.v17.i4.419. Review.

14.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK.

Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9.

15.

Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.

Zhu Y, Jiang JL, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ, Lee K, Kudo M, Canfield WM, Edmunds T, Jiang C, Mattaliano RJ, Cheng SH.

Mol Ther. 2009 Jun;17(6):954-63. doi: 10.1038/mt.2009.37.

16.

Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil.

Engel M, Malta FM, Gomes MM, Mello IM, Pinho JR, Ono-Nita SK, Carrilho FJ.

BMC Public Health. 2007 Apr 4;7:50.

17.

Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.

Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, Al-Marri A, Amer AM, Morad N, Bener A.

World J Gastroenterol. 2006 Sep 21;12(35):5692-8.

Items per page

Supplemental Content

Support Center